Madrigal Pharmaceuticals (MDGL) Debt to Equity: 2010-2025
Historic Debt to Equity for Madrigal Pharmaceuticals (MDGL) over the last 9 years, with Sep 2025 value amounting to $0.54.
- Madrigal Pharmaceuticals' Debt to Equity rose 260.39% to $0.54 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.54, marking a year-over-year increase of 260.39%. This contributed to the annual value of $0.16 for FY2024, which is 45.30% down from last year.
- Madrigal Pharmaceuticals' Debt to Equity amounted to $0.54 in Q3 2025, which was up 219.23% from $0.17 recorded in Q2 2025.
- Madrigal Pharmaceuticals' 5-year Debt to Equity high stood at $5.16 for Q3 2023, and its period low was $0.14 during Q2 2024.
- For the 3-year period, Madrigal Pharmaceuticals' Debt to Equity averaged around $0.77, with its median value being $0.17 (2025).
- As far as peak fluctuations go, Madrigal Pharmaceuticals' Debt to Equity tumbled by 97.08% in 2024, and later skyrocketed by 260.39% in 2025.
- Quarterly analysis of 4 years shows Madrigal Pharmaceuticals' Debt to Equity stood at $0.25 in 2022, then increased by 14.10% to $0.28 in 2023, then slumped by 45.30% to $0.16 in 2024, then skyrocketed by 260.39% to $0.54 in 2025.
- Its Debt to Equity stands at $0.54 for Q3 2025, versus $0.17 for Q2 2025 and $0.17 for Q1 2025.